701: Cardiac safety of ultra-Hypofractionated RT in the HYPORT Adjuvant randomized trial (NCT03788213)

Sanjoy Chatterjee(Tata Medical Center), HYPORT Adjuvant Trialists Group, N. Bathija, Shagun Misra, Rajesh Balakrishnan, Punita Lal, Anurupa Mahata(Tata Medical Center), Patricia Solomon, Santam Chakraborty(Tata Medical Center), S. Mandal(Bose Institute)

Radiotherapy and Oncology

May 1, 2024

10.1016/s0167-8140(24)01254-4

Cited by 1

Related Papers

HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results – Interim analysis

|Radiotherapy and Oncology|2022|42

Resource requirements and reduction in cardiac mortality from deep inspiration breath hold (DIBH) radiation therapy for left sided breast cancer patients: A prospective service development analysis

|Practical Radiation Oncology|2018|32

Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)—study protocol for a multicentre, randomized phase III trial

|Trials|2020|29

Oral cavity adjuvant therapy (OCAT) -a phase III, randomized controlled trial of surgery followed by conventional RT (5 fr/wk) versus concurrent CT-RT versus accelerated RT (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity

|European Journal of Cancer|2022|29

Alleviating Morbidity From Locally Advanced Breast Cancer Using a Practical and Short Radiation Therapy Regimen: Results of the HYPORT Palliative Studies

|International Journal of Radiation Oncology*Biology*Physics|2023|22